Ibrutinib: ibrutinib treatment which blocks BCR signaling also interferes with metabolic pathways in CLL, decreasing mitochondrial oxidative respiration, glycolysis and glutamine metabolism [400,427,428] An increase in glutamine uptake is also observed in ibrutinib-resistant CLL cells, and etomoxir treatment (that blocks the mitochondrial import of FAs and their βeta-oxidation), has a cytotoxic effect on ibrutinib resistant CLL cells [377]. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.